...
首页> 外文期刊>Cancer gene therapy >Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells
【24h】

Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells

机译:RNAi对bcl-2和xIAP的特异性下调增强了MCF-7人乳腺癌细胞中化学治疗剂的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Antiapoptotic genes such as bcl-2 or xIAP may be responsible for resistance to apoptosis induced by cytotoxic drugs. The aim of this study was to investigate if downregulation of bcl-2 or xIAP by RNA interference (RNAi) would sensitize MCF-7 cells to etoposide and doxorubicin. FITC-siRNAs uptake was verified by fluorescence microscopy and downregulation of Bcl-2 or XIAP was confirmed by Western Blotting. Both siRNAs reduced the number of viable cells and increased cellular apoptosis. Treatment with siRNAs followed by treatment with etoposide or doxorubicin further reduced the number of viable cells, when compared to either of the treatments alone. Therefore, downregulation of bcl-2 or xIAP by RNAi enhances the effects of etoposide and doxorubicin.
机译:抗凋亡基因(例如bcl-2或xIAP)可能对细胞毒性药物诱导的凋亡产生抗性。这项研究的目的是研究RNA干扰(RNAi)对bcl-2或xIAP的下调是否会使MCF-7细胞对依托泊苷和阿霉素敏感。通过荧光显微镜证实FITC-siRNA的摄取,并且通过蛋白质印迹证实Bcl-2或XIAP的下调。两种siRNA均减少了存活细胞的数量并增加了细胞凋亡。与单独的两种治疗方法相比,用siRNA处理后再用依托泊苷或阿霉素处理可进一步减少活细胞的数量。因此,RNAi对bcl-2或xIAP的下调增强了依托泊苷和阿霉素的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号